CStone opens hot with 2019’s first HK biotech IPO
CStone Pharmaceuticals has launched Hong Kong’s first biotechnology IPO of the year — and bankers are watching it closely. The up to HK$2.38bn ($304m) deal has received a strong early response, a good sign for the growing pipeline of biotech issuers hoping to put a difficult 2018 behind them. Jonathan Breen reports.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: